The Ann was on 22/12/22, and the thread includes DT quoted from...

The Ann was on 22/12/22, and the thread includes DT quoted from FB:

"With EMD AML we need to create a change in thinking by haematologists that it is much more common than they think and they need to screen for it As you need to treat it differently. Accomplishing this requires leadership from the top cancer centres. On top of this our US EMD AML trial program will requires the support of the top KOLs to be a success."

"This is a more a medium to long term project that will make our EMD AML opportunity more valuable to any buyer. These longer term projects need to be undertaken sooner rather than later to have any impact on value in the medium term’’